READLINE was established in 2013. The company is headquartered in the "National Science and Technology Business Incubator" in Shenzhen Nanshan Hi-tech Industrial Park. It is an innovative group company integrating R&D, production, sales, and investment. There are three subsidiaries in the group company: Shenzhen Readline Biotechnology Co., Ltd. which focuses on the applications of immobilized enzymes technology, Shenzhen Readline Technology Co., Ltd. which specializes in import and export trade, and Shenzhen Readline Venture Capital Partnership (Limited Partnership) which focuses on venture capital in the medical and health field.
Shenzhen Readline Technology Co., Ltd. was established in 2013. The company focuses on the export of high-quality peptide products from Chinese peptide industry chain, and realizes one-stop purchase of peptide products for international customers. The company's products include: protected amino acids, cosmetics peptide, medical injection pens, custom synthesized peptides, peptide APIs, synthetic resins, coupling reagents, peptide devices (synthesis, pyrolysis, purification, nanofiltration, rotary evaporator, lyophilizer, etc.), etc.; the company also undertakes the marketization business of internationally innovative medical devices, drugs, and medical services in China. The company provides consulting services on domestic laws and regulations for related products and services, product access contractors, partner recommendations, and signing of related equity documents.
Founded in 2017, Shenzhen Readline Biotechnology Co., Ltd. is an innovative high-tech enterprise led by two postdoctoral fellows in the United States, two leading talents in Shenzhen, three university professors, and several listed corporate executives. The company is committed to the applications of immobilized enzymes technology to the development of products such as peptides, polysaccharides, and non-natural amino acids. The products developed are widely used in medicine, health products, cosmetics, food, feed and other industries. The company adopts multidisciplinary technologies of chemistry, materials science and life sciences, which greatly reduces the dependence on the traditional chemical industry and the emission of "three wastes", and realizes the green production while improving product quality and economic benefits.
Shenzhen Readline Venture Capital Partnership (Limited Partnership) was established in 2017. The company focuses on the investment in entrepreneurial healthcare projects. The company is composed of two leading talents in Shenzhen, a world top 500 corporate finance expert, and a director of a charitable foundation. The company is now intensively engaged in the integration and the achievement of the competitive advantage of Chinese peptide industrial chain in the world. The companies currently investing include Chengdu Zhengyuan Biochemical Technology Co., Ltd., Shenzhen Readline Biotechnology Co., Ltd., and two new peptide drug R&D companies.